✓ Translated by DotMD AI Clinical Council Source: Breast cancer (Tokyo, Japan) • Phase III Randomized Trial
Verify Primary Source: NIH PubMed PMID #41910921 ↗

Phase III Randomized Trial: Minimal important differences of EORTC QLQ-C30 and QLQ-BR23 for metastatic breast cancer patients in a Japanese population: results from the RESQ trial (N = 302)

Original Paper Title: “Minimal important differences of EORTC QLQ-C30 and QLQ-BR23 for metastatic breast cancer patients in a Japanese population: results from the RESQ trial”

Elena Rostova (AI Quant) Rigor Score
87 / 100
Sample Size (Participants)
N = 302
Evidence Classification
Phase III Randomized Trial
Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways
  • CONCLUSIONS: This study provides the first MID estimates for the QLQ-BR23 and expands MID for the QLQ-C30 in patients with metastatic breast cancer. These findings offer benchmarks for interpreting quality-of-life outcomes and support the clinical relevance of patient-reported measures.[ 250 / 250 ].
  • Study Design & Sample: Phase III Randomized Trial published in Breast cancer (Tokyo, Japan) (N = 302 human participants).
  • Biostatistical Rigor Score: 87/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in Breast cancer (Tokyo, Japan) (2026), this phase iii randomized trial evaluating 302 human participants investigated: BACKGROUND: European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) and breast cancer–specific quality-of-life questionnaire (QLQ-BR23) are widely used in clinical trials, but information on minimal important differences (MIDs) remain limited. Key clinical takeaway: CONCLUSIONS: This study provides the first MID estimates for the QLQ-BR23 and expands MID for the QLQ-C30 in patients with metastatic breast cancer. These findings offer benchmarks for interpreting quality-of-life outcomes...

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (Breast cancer (Tokyo, Japan), 2026-05-15; N = 302; Rigor 87/100): CONCLUSIONS: This study provides the first MID estimates for the QLQ-BR23 and expands MID for the QLQ-C30 in patients with metastatic breast cancer. These findings offer benchmarks for interpreting quality-of-life outcomes and support the clinical relevance of patient-reported measures.[ 250 / 250 ].

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Rx: quality-choice-effervescent-cold-relief-plus-aspirin-chlorpheniramine → Rx: quality-choice-pain-relief-powder-aspirin-and-caffeine → Rx: eribulin-mesylate → Rx: bio-combination-28-schuessler-salts → Condition: tubular-adenocarcinoma → Condition: serous-cystadenocarcinoma →
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 41910921: Phase III Randomized Trial: Minimal important differences of EORTC QLQ-C30 and QLQ-BR23 for metastatic breast cancer patients in a Japanese population: results from the RESQ trial (N = 302)

3 of 3 Free Questions Remaining